Venclexta, developed by AbbVie and Genentech has received FDA accelerated approval for the treatment of people with chronic lymphocytic leukemia who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. This is Genentech’s tenth new medicine approved in the past seven years.